Additive impact of diabetes and sarcopenia on all-cause and cardiovascular mortality: A longitudinal nationwide population-based study
- PMID: 37611822
- DOI: 10.1016/j.metabol.2023.155678
Additive impact of diabetes and sarcopenia on all-cause and cardiovascular mortality: A longitudinal nationwide population-based study
Abstract
Objective: Diabetes mellitus (DM) and sarcopenia (SP) are growing public health concerns in an aging society, which share common pathophysiological mechanisms and are associated with serious health consequences. We investigated the impact of DM and SP on all-cause and cardiovascular mortalities in a longitudinal nationwide population-based study.
Methods: The study analyzed data from the Korea National Health and Nutrition Examination Survey conducted between 2008 and 2011, including information on appendicular skeletal muscle mass data. Mortality data up to December 2020 were retrieved from the National Death Registry.
Results: Among the 17,920 participants, 14,737 (82.2 %) had neither DM nor SP (DM-/SP-), 1349 (7.5 %) had only DM (DM+/SP-), 1425 (8.0 %) had only SP (DM-/SP+), and 409 (2.3 %) had both DM and SP (DM+/SP+). Compared to the DM-/SP- group, the DM-/SP+ and DM+/SP+ groups demonstrated increased all-cause mortality with adjusted hazard ratios (HRs) of 1.47 (95 % confidence interval [CI]: 1.14-1.89) and 1.85 (95 % CI: 1.28-2.69), respectively, while the DM+/SP- group did not (HR 1.29, 95 % CI: 0.97-1.74). The DM+/SP+ group demonstrated the highest risk of overall mortality (p-for-trend <0.001). Compared to the DM-/SP- group, only the DM+/SP+ group demonstrated increased cardiovascular mortality with HRs of 2.10 (95 % CI: 1.11-4.00) while the DM+/SP- (HR 1.35, 95 % CI: 0.79-2.30) and DM-/SP+ (HR 1.42, 95 % CI: 0.84-2.43) groups did not.
Conclusions: The coexistence of DM and SP additively increased the risk of all-cause and cardiovascular mortality. Individuals with either disease may require more careful management to prevent the development of the other disease to reduce mortality.
Keywords: All-cause mortality; Cardiovascular mortality; Diabetes mellitus; Sarcopenia.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest We declare no competing interests.
Similar articles
-
Additive impact of diabetes and Helicobacter pylori infection on all-cause mortality, diabetic mortality, and cardiovascular mortality: a longitudinal nationwide population-based study.Diabetol Metab Syndr. 2024 Aug 30;16(1):212. doi: 10.1186/s13098-024-01437-2. Diabetol Metab Syndr. 2024. PMID: 39210497 Free PMC article.
-
Additive impact of metabolic syndrome and sarcopenia on all-cause and cause-specific mortality: an analysis of NHANES.Front Endocrinol (Lausanne). 2025 Feb 10;15:1448395. doi: 10.3389/fendo.2024.1448395. eCollection 2024. Front Endocrinol (Lausanne). 2025. PMID: 39995525 Free PMC article.
-
Association of metabolic syndrome and sarcopenia with all-cause and cardiovascular mortality: a prospective cohort study based on the NHANES.Front Endocrinol (Lausanne). 2024 Mar 26;15:1346669. doi: 10.3389/fendo.2024.1346669. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38596221 Free PMC article.
-
Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey.J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):964-972. doi: 10.1002/jcsm.12719. Epub 2021 Jun 2. J Cachexia Sarcopenia Muscle. 2021. PMID: 34080327 Free PMC article.
-
Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials.Am J Cardiovasc Drugs. 2023 Mar;23(2):113-126. doi: 10.1007/s40256-022-00561-6. Epub 2022 Dec 27. Am J Cardiovasc Drugs. 2023. PMID: 36572841
Cited by
-
Additive effect of diabetes mellitus on the prevalence and prognosis of sarcopenic obesity: Implications for all-cause mortality.PLoS One. 2025 Jun 10;20(6):e0325423. doi: 10.1371/journal.pone.0325423. eCollection 2025. PLoS One. 2025. PMID: 40493627 Free PMC article.
-
Metabolic-associated fatty liver disease and sarcopenia: A double whammy.World J Hepatol. 2024 Feb 27;16(2):152-163. doi: 10.4254/wjh.v16.i2.152. World J Hepatol. 2024. PMID: 38495287 Free PMC article. Review.
-
Impact of Adipose Tissue and Lipids on Skeletal Muscle in Sarcopenia.J Cachexia Sarcopenia Muscle. 2025;16(4):e70000. doi: 10.1002/jcsm.70000. J Cachexia Sarcopenia Muscle. 2025. PMID: 40641114 Free PMC article. Review.
-
Caffeine intake is nonlinearly associated with muscle mass in young and middle-aged US adults.BMC Musculoskelet Disord. 2024 Nov 19;25(1):929. doi: 10.1186/s12891-024-08063-z. BMC Musculoskelet Disord. 2024. PMID: 39563256 Free PMC article.
-
The Diminished Cardiorespiratory Fitness in Cardiovascular-Kidney-Metabolic Syndrome.J Multidiscip Healthc. 2025 Feb 21;18:1081-1090. doi: 10.2147/JMDH.S508981. eCollection 2025. J Multidiscip Healthc. 2025. PMID: 40008289 Free PMC article.
LinkOut - more resources
Full Text Sources